marked.bio

multi-kinase inhibitor · small molecule

zanzalintinib

3 active trials across 2 of our biomarkers, targeting VEGFR/MET/TAM. Not approved for any biomarker on marked.bio yet.

Also known as XL092.

Counts only trials that select patients by one of the biomarkers on marked.bio, not every trial of this drug.

Biomarkers

BiomarkerActive trialsAll trialsFurthest active phase
BRAF V600E 2 2 Phase 1
MSI-H / dMMR 2 2 Phase 3

Sponsors

Industry sponsors leading active biomarker-selected trials of zanzalintinib.

  1. Exelixis 2

Trials

3 of 3 trials shown

  1. Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

    Active, not recruiting Phase 3 Exelixis Started 2022Primary completion 2026-06 NCT05425940

    zanzalintinibatezolizumab FDAregorafenib

    Documented NOT to have microsatellite instability-high (MSI-high) or mismatch repair deficient (dMMR) CRC by tissue-based analysis.

    MSI-H / dMMRColorectal Cancer

  2. XL092 and Cemiplimab in BRAF WT Thyroid Cancer

    Recruiting Phase 1 UNC Lineberger Comprehensive Cancer Center Started 2025Primary completion 2028-03 NCT06902376

    cemiplimabzanzalintinib

    Must have BRAF V600E mutation-negative tumor, as determined by BRAF V600E immunohistochemistry on tumor tissue…

    BRAF V600EAnaplastic Thyroid Cancer, Thyroid Cancer, BRAF Mutation-Related Tumors

  3. A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors

    Active, not recruiting Phase 1 Exelixis Started 2019Primary completion 2026-08 NCT03845166

    zanzalintinibatezolizumab FDAavelumab

    BRAF inhibitor (in combination with cetuximab +/- binimetinib) for subjects with BRAF V600E mutations

    BRAF V600EMSI-H / dMMRNeoplasm Malignant, Renal Cell Carcinoma, Hormone Receptor Positive Breast Carcinoma, Metastatic Castration-resistant Prostate Cancer